Dose-dense anthracycline-based chemotherapy for node-positive breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3637-3643

  Ellis, Georgiana K ^a   Livingston, Robert B ^a   Gralow, Julie R ^a   Green, Stephanie J ^a   Thompson, Tove ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAPSONE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROCHLORPERAZINE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMORRHAGIC CYSTITIS; HOSPITALIZATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; ONCOGENE NEU; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; SURVIVAL RATE; UNITED STATES;

EID: 0036731486     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.113     Document Type: Article

References (23)

1. Dose intensity and high dose therapy
2. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
3. Adjuvant breast cancer therapy: Current status and future strategies-growth kinetic and the improved drug therapy of breast cancer
4. 5-Year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
5. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
6. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
7. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a phase I-II study of doxorubicin-treated patients
8. Docetaxel + vinorelbine with concurrent G-SCF support: Phase II study in stage IV breast cancer
9. Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a southwest oncology group phase II study
10. All patients with the t(11:16)(q23;p13.3) that involves MLL and CBP have treatment related hematologic disorders
11. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience
12. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience
13. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: Analysis of serial marrow samples from normal donors
14. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia: The International Acute Myeloid Leukemia Study Group
15. Multilineage response in aplastic anemia patients following long term administration of filgrastim (recombinant human granulocyte colony stimulating factor)
16. The importance of dose-intensity in chemotherapy of metastatic breast cancer
17. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
18. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
19. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence on in situ carcinoma
20. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
21. Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial
22. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
23. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status